NARA Discovery
Article Details
← Back to Search Results
Journal Article

Molecular characterization of extended-spectrum β-lactamases-producing Escherichia coli isolated from patients with bacteremia

Beatrice D. V. L. Souza; Guilherme Solveira; Guilherme F. R. de Souza; Henrique Orsi; Daiany R. P. De Lira; Iranildo do A. Fernandes; Adriano M. Ferreira; Alessandro L. Mondelli; Claudio T. Sacchi; Karoline R. Campos; Marlon B. N. Santos; Carlos H. Camargo; Rodrigo T. Hernandes
Brazilian Journal of Microbiology · Vol. 57, Issue 1 · 2026

Abstract

Bacteremia is a major health problem that affects millions of people worldwide. E. coli is one of the main pathogens associated with bacteremia and its resistance to the antimicrobial drugs, including β-lactams, has significantly increased in recent years. In view of the above, our objective was to determine the antimicrobial resistance profile of 60 E. coli isolates obtained from patients with bacteremia, as well as to characterize extended-spectrum β-lactamases (ESBL) -producing isolates. The highest resistance rates were observed for ciprofloxacin (33.3%), levofloxacin (31.7%), cefuroxime (20%) and cefotaxime (20%). Furthermore, 12 isolates (20%) were ESBL producers. Genomic analysis showed that 58.3% of these ESBL-producing isolates belonged to the phylogroup B2, ST131, serotype O25:H4 and carried the following ESBL-encoding genes: bla CTX−M−15 (66.7%), bla CTX−M−8 (16.7%), bla CTX−M−2 (8.7%) or bla CTX−M−27 (8.7%). Our data highlight the high frequency of E. coli ST131 among the ESBL-producing isolates obtained from patients with bacteremia in Botucatu, Brazil.

Bibliographic Information

JournalBrazilian Journal of Microbiology
PublisherSpringer
Publication Date2026-12-01
Publication Year2026
Volume57
Issue1
Document TypeJournal Article
Print ISSN1517-8382
eISSN1678-4405
DOI10.1007/s42770-026-02018-3

Access Information

NARA Access Coverage2019-01-01~Current
Journal Homepagehttps://www.springer.com/journal/42770
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.